Figure 3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study

<jats:p>&lt;p&gt;Kaplan–Meier landmark analysis of EFS among patients with ongoing remission without new anticancer therapies by (&lt;b&gt;A&lt;/b&gt;) CAR T-cell persistence status, by ddPCR, at month 3 (&lt;b&gt;B&lt;/b&gt;) CAR T-cell persistence status, by ddPCR, at month 6, and (&lt;b&gt;C&lt;/b&gt;) BCA status at month 6 after obe-cel infusion.&lt;/p&gt;</jats:p>